Literature DB >> 16718845

Updates on esophageal and gastric cancers.

Amy Gallo1, Charles Cha.   

Abstract

Esophageal and gastric cancers are both common and deadly. Patients present most often after disease progression and survival is therefore poor. Due to demographic variability and recent changes in disease incidence, much emphasis has been placed on studying risk factors for both esophageal and gastric cancers. However, with increasing understanding of these diseases, low survival rates persist and continued intensive studies are necessary to optimize treatment plans. This review article discusses updates in the evolving epidemiology, clinical presentation, risk factors, and diagnostic and treatment modalities of esophageal and gastric cancers.

Entities:  

Mesh:

Year:  2006        PMID: 16718845      PMCID: PMC4087968          DOI: 10.3748/wjg.v12.i20.3237

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

1.  Targeting the optimal extent of lymph node dissection for gastric cancer.

Authors:  Dimitrios H Roukos; Angelos M Kappas
Journal:  J Surg Oncol       Date:  2002-10       Impact factor: 3.454

2.  Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Authors:  J Lagergren; R Bergström; O Nyrén
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

3.  Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: risk factors and management.

Authors:  S Michael Griffin; Ian H Shaw; Samuel M Dresner
Journal:  J Am Coll Surg       Date:  2002-03       Impact factor: 6.113

4.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; J J Bonenkamp; E Klein Kranenbarg; I Songun; K Welvaart; J H J M van Krieken; S Meijer; J T M Plukker; P J van Elk; H Obertop; D J Gouma; J J B van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus; M Sasako
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

5.  Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.

Authors:  Thomas W Rice; David J Adelstein; Mark A Chidel; Lisa A Rybicki; Malcolm M DeCamp; Sudish C Murthy; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2003-11       Impact factor: 5.209

6.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.

Authors:  Benjamin Chun-Yu Wong; Shiu Kum Lam; Wai Man Wong; Jian Shun Chen; Ting Ting Zheng; Rui E Feng; Kam Chuen Lai; Wayne Hsing Cheng Hu; Siu Tsan Yuen; Suet Yi Leung; Daniel Yee Tak Fong; Joanna Ho; Chi Kong Ching; Jun Shi Chen
Journal:  JAMA       Date:  2004-01-14       Impact factor: 56.272

8.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

9.  Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.

Authors:  D Y Graham; J T Schwartz; G D Cain; F Gyorkey
Journal:  Gastroenterology       Date:  1982-02       Impact factor: 22.682

10.  How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study.

Authors:  Anne-Marie Bouvier; Olivier Haas; Françoise Piard; Philippe Roignot; Claire Bonithon-Kopp; Jean Faivre
Journal:  Cancer       Date:  2002-06-01       Impact factor: 6.860

View more
  47 in total

Review 1.  Current management and future strategies of gastric cancer.

Authors:  Joong Ho Lee; Kyung Min Kim; Jae-Ho Cheong; Sung Hoon Noh
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

2.  A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer.

Authors:  Yoshiyuki Fujiwara; Keijiro Sugimura; Hiroshi Miyata; Takeshi Omori; Hiroyuki Nakano; Chie Mochizuki; Katsuji Shimizu; Hiroaki Saito; Keigo Ashida; Soichiro Honjyo; Yusuke Nakamura; Masahiko Yano
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

3.  Monitoring with sensitive tumor markers contributes to decision-making and better prognosis in gastric cancer patients with peritoneal recurrence.

Authors:  Takuma Ohashi; Shuhei Komatsu; Daisuke Ichikawa; Toshiyuki Kosuga; Kazuma Okamoto; Tomohiro Arita; Hirotaka Konishi; Ryo Morimura; Yasutoshi Murayama; Atsushi Shiozaki; Yoshiaki Kuriu; Hisashi Ikoma; Masayoshi Nakanishi; Hitoshi Fujiwara; Eigo Otsuji
Journal:  Int J Clin Oncol       Date:  2017-05-09       Impact factor: 3.402

4.  Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to tumor invasion and Epstein-Barr virus status in gastric cancer.

Authors:  Hiroshi Uozaki; Rita Rani Barua; Sun Minhua; Tetsuo Ushiku; Rumi Hino; Aya Shinozaki; Takashi Sakatani; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2011-03-01

5.  MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer.

Authors:  Zhongxue Su; Juan Zhao; Zhonghou Rong; Wenmao Geng; Zhiyi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

6.  Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.

Authors:  Dimitra Florou; Christos Patsis; Alexandros Ardavanis; Andreas Scorilas
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

7.  Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites.

Authors:  Sungshim Lani Park; Shen-Chih Chang; Lin Cai; Carlos Cordon-Cardo; Bao-Guo Ding; Sander Greenland; Shehnaz K Hussain; Qingwu Jiang; Simin Liu; Ming-Lan Lu; Jenny T Mao; Hal Morgenstern; Li-Na Mu; Leslie J Ng; Allan Pantuck; Jianyu Rao; Victor E Reuter; Donald P Tashkin; Nai-Chieh Y You; Can-Qing Yu; Shun-Zhang Yu; Jin-Kou Zhao; Arie Belldegrun; Zuo-Feng Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

8.  Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway.

Authors:  Guo-Qing Li; Juan Xie; Xiao-Yong Lei; Li Zhang
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

9.  Cumulative total S-1 dose in adjuvant chemotherapy affects the long-term outcome following curative gastrectomy for gastric cancer.

Authors:  Keiji Nishibeppu; Shuhei Komatsu; Toshiyuki Kosuga; Takeshi Kubota; Kazuma Okamoto; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

10.  Efficacy of adjuvant chemotherapy combined with immunotherapy with cytokine-induced killer cells for gastric cancer after d2 gastrectomy.

Authors:  Yu Chen; Zeng-Qing Guo; Chun-Mei Shi; Zhi-Feng Zhou; Yun-Bin Ye; Qiang Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.